Focusing on innovative cancer treatment, the book presents two groundbreaking drug compounds, PT162 and PT167, developed to exploit the Warburg effect in cancer cells. Both drugs demonstrate remarkable efficacy, completely halting cancer cell growth and inducing apoptosis through the reactivation of p53 function. PT162, a novel compound, and PT166, a new colchicinoid derivative, were combined to create PT167, which effectively targets a wide range of cancer types, including leukemia. The author details the synthesis and testing results, proposing a new strategy for cancer therapy.
Oxygen has two gaseous forms (dioxygen and ozone) and six solid allotropic modifications, with cyclooctaoxygen being a predicted form since 1990. Its first synthesis and characterization occurred in 2016 as a sodium crown complex, isolated in cytosine nucleoside hydrochloride complexes. Cyclooctaoxygen sodium was synthesized in vitro from atmospheric oxygen or catalase-generated oxygen, catalyzed by cytosine nucleosides and ninhydrin or low-molecular weight RNA. Thin-layer chromatographic mobility shift assays demonstrated that this cationic complex binds to nucleic acids (RNA and DNA), associates with single-stranded DNA and spermine phosphate, and is non-toxic to cultured mammalian cells at concentrations of 0.1–1.0 mM. It is hypothesized that cyclooctaoxygen forms in eukaryotic cells from dihydrogen peroxide via a catalase reaction involving cytidine and RNA. A molecular biological model suggests an epigenetic shell for eukaryotic DNA, incorporating selenium's interactions. The sperminium hydrogen phosphate/cyclooctaoxygen sodium complex is thought to cover actively transcribed regions of the genome. Cyclooctaoxygen is absent in hypoxic, condensed chromatin, indicating its role in gene regulation and proto-eukaryotic evolution. Glyphosate and its metabolite AMPA are identified as ‘epigenetic poisons’ that destroy the cyclooctaoxygen sodium complex, posing a risk to eukaryotic genomic integrity.
